They associated the increased survival following OVV-CXCR4-A-mFc treatment with a reduction of CXCL12 and VEGF as well as cancer-initiating, endothelial, myeloid and plasmacytoid dendritic cells in the tumor microenvironment. The gene discussed is CXCL12; the disease is neoplasm.